Clinical trial
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors…
NCT00003993 · National Institute on Aging (NIA), NIH · Completed
Key facts
| NCT number | NCT00003993 |
|---|---|
| Title | Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma |
| Official title | A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells |
| Lead sponsor | National Institute on Aging (NIA), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, bryostatin 1 |
| Enrollment | 24 |
| Start date | Sep 1, 1999 |
| Primary completion | Jul 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: